Clinical Trial Update: Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)

View source ↗

Summary

A pre-approval access, single-patient request for the niraparib and abiraterone acetate combination in metastatic castration-resistant prostate cancer has been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Niraparib (Niraparib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Metastatic Castration-resistant Prostate Cancer | Status: APPROVED_FOR_MARKETING